Supplementary Figure 1. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis
figureposted on 15.10.2021, 15:08 by Saaya Tsutsué, Takahiro Suzuki, Hyojin Kim, Bruce Crawford
Supplementary Figure 1. Patient survival (A) overall (B) by age-group (C) by 1L. Patients were categorized by treatment regimen received in the 1L of therapy. AZA, azacitidine; ESA, erythropoiesis-stimulating agents.